Evolent Health Inc Cl A Com (EVH) Stock Price, Quote & News

Company Profile

Evolent Health, Inc., through its subsidiary, provides specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company offers integrated value-based care platform for health plan administration and management. It also provides administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggreg...

Industry: Health Information Services

Sector: Healthcare

Phone: 571 389 6000

Website: www.evolent.com

Address:

1812 N. Moore Street, Suite 1705, Arlington, United States

PeakedSeller Mar. 14 at 1:13 PM

$EVH 🔥 Oncology surging to 65% of 2026 revenue + $900M Performance Suite ramp with Highmark partnership firing up. AI savings accelerating + 98% retention rock solid. Crushed near $3 (yes that is a 300 million market cap)— loading this dip hard! 🚀💎 Once the market comes to their senses and rerated this thing like they did back in 2020 (yes I rode that wave too) it will be a crazy move!!!!

0 · Reply

PeakedSeller Mar. 14 at 1:11 PM

$MYGN $EVH my two undervalued healthcare picks for 2026… EVH has a more ayssymmetric upside with higher risk on the debt side. Execution equals 300-500% gain in less than a year MYGN is just a safe double bagger with their new MRD launch (read the data, it’s amazing).

0 · Reply

PeakedSeller Mar. 14 at 1:06 PM

$EVH 🚀 this is a screaming buy at these levels! Evolent Health just dropped strong Q4 beats and is guiding ~30% revenue growth in 2026 to ~$2.5B midpoint — powered by oncology dominance (heading to 65% mix), massive new enhanced contracts, and 90%+ shift to high-margin Performance Suite. Add 98% customer retention, AI cost savings, and conservative guidance that sets up a huge H2 EBITDA ramp… THE RECOVERY FOR THIS STOCK WILL BE VIOLENT!!! Value-based care is exploding — $EVH is perfectly positioned to win big. Dip buyers loading up! 💥📈 #EVH #HealthcareStocks #ValueBasedCare

0 · Reply

St0ckJunkie13 Mar. 13 at 5:56 PM

$EVH hitting the floor, cant realistically see profit until 2028

1 · Reply

PatBtmn Mar. 13 at 5:42 PM

$EVH ouch

0 · Reply

TOMKiLA Mar. 12 at 1:43 PM

$EVH a range between 2.5 and 3.5$ is the best opportunity for us because in the coming 12/18/24 months everything will change. The margin are still lower than the forecast, the new contract should increase the value of ebitda quickly For example, evolent signed a deal for 550m $ in 2026 and $800M in 2027. It’s the same contract but the value will be higher in 2027. Imagine how much money evolent should made within 2 years with 20/30 new contracts

1 · Reply

PeakedSeller Mar. 12 at 12:00 AM

$EVH 🔥 The market-cap-to-revenue mismatch here is straight-up absurd. EVH: $337M market cap vs $2.5 BILLION 2026 revenue guidance (midpoint of $2.4–2.6B, +30% growth, oncology ramping to 65% of mix, $900M new Performance Suite contracts already signed). That’s 0.13x P/S. Now compare to similar healthcare services peers: • Privia Health (PRVA): ~0.95x P/S • AMN Healthcare (AMN): ~0.32x P/S (but slower growth) • Sector median for comparable companies: 0.8–1.2x P/S Same industry. Larger revenue scale. Visible EBITDA/FCF path.

0 · Reply

PeakedSeller Mar. 11 at 11:53 PM

$EVH 🔥 This valuation is honestly ridiculous. EVH is trading at just $3.02 with a tiny $337M market cap… …while guiding $2.4–2.6 BILLION in revenue for 2026 (+30% growth) and $110–140M adjusted EBITDA. Oncology is ramping hard toward 65% of the mix, backed by $900M in new Performance Suite contracts already signed and coming online in H2. This is a legitimate $2.5 billion revenue company trading at under 0.5x EV/Sales. The market completely overreacted to temporary H1 margin pressure from new contract onboarding and one non-cash impairment. Simple execution on what they’ve already guided should close this massive disconnect fast. One of the most ridiculously undervalued setups in the entire market right now. This is EASILY a $10-12 stock if they simply follow through with projections this year

0 · Reply

St0ckJunkie13 Mar. 11 at 4:29 PM

$EVH selling all my shares if it goes above $3.00, to much instatutional manipulation and this company has yet to address its share price tanking and have done little to nothing to maximize shareholder value. Expect tto see $EVH at $1.50 by july

1 · Reply

riedela Mar. 11 at 1:51 PM

$EVH 2.92 buying back my 120k shares all the way to bottom (again) had 230k at one point at 3.64 average. Sad times 😒 if I held 😞

1 · Reply

Evolent to Participate in Upcoming Investor Conferences

Feb 26, 2026, 10:38 AM EST - 17 days ago

Evolent Health: Cheap, Levered, But Ready To Rebound

Feb 25, 2026, 12:27 PM EST - 18 days ago

Evolent Health, Inc. (EVH) Q4 2025 Earnings Call Transcript

Feb 24, 2026, 4:10 PM EST - 19 days ago

Evolent Announces Fourth Quarter 2025 Results and Full Year 2025 Results

Feb 4, 2026, 11:02 AM EST - 5 weeks ago

Evolent To Release 2025 Fourth Quarter and Year-End Financial Results on Tuesday, February 24, 2026

Jan 2, 2026, 4:15 PM EST - 2 months ago

Evolent Reports Inducement Award Under NYSE Listing Rule 303A.08

Nov 11, 2025, 10:21 PM EST - 4 months ago

Evolent Health, Inc. (EVH) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 7, 2025, 2:46 PM EST - 4 months ago

Evolent Health, Inc. (EVH) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:12 PM EST - 4 months ago

Evolent and American Oncology Network unveil innovative model seeking to improve cancer care while eliminating prior authorization burden

Nov 6, 2025, 4:10 PM EST - 4 months ago

Evolent Announces Third Quarter 2025 Results

Oct 9, 2025, 8:30 AM EDT - 5 months ago

Evolent To Release Third Quarter 2025 Financial Results on Thursday, November 6, 2025

Sep 23, 2025, 4:10 PM EDT - 6 months ago

Evolent Announces Strategic Divestiture of its Value-Based Primary Care Business, Evolent Care Partners

PRVA

Aug 21, 2025, 8:35 AM EDT - 7 months ago

Evolent's Soft Q2 Results: Why I'm Holding Anyway

Aug 19, 2025, 7:00 AM EDT - 7 months ago

Evolent Health, Inc. Announces Pricing of Oversubscribed and Upsized $145.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock

Aug 18, 2025, 4:05 PM EDT - 7 months ago

Evolent Health, Inc. Announces Proposed Offering of $140.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock

Aug 8, 2025, 6:15 PM EDT - 7 months ago

Evolent Health, Inc. (EVH) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:10 PM EDT - 7 months ago

Evolent Announces Second Quarter 2025 Results

Jul 14, 2025, 8:00 AM EDT - 8 months ago

Evolent To Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Jul 9, 2025, 8:00 AM EDT - 8 months ago

Evolent announces key appointments to leadership team

Jun 20, 2025, 6:30 AM EDT - 9 months ago

Evolent reiterates Q2 and full year guidance for Adjusted EBITDA

May 9, 2025, 6:03 PM EDT - 11 months ago

Evolent Health, Inc. (EVH) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:10 PM EDT - 11 months ago

Evolent Announces First Quarter 2025 Results

Apr 22, 2025, 6:30 AM EDT - 11 months ago

Evolent names Shawn Guertin as new independent nominee for election to its Board of Directors

Apr 15, 2025, 9:00 AM EDT - 11 months ago

Evolent program achieves 20% reduction in use of low-value oncology regimens

Apr 10, 2025, 5:00 PM EDT - 1 year ago

Evolent To Release First Quarter 2025 Financial Results on Thursday, May 8, 2025

Feb 20, 2025, 7:28 PM EST - 1 year ago

Evolent Health, Inc. (EVH) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 4:10 PM EST - 1 year ago

Evolent Announces Fourth Quarter and Full Year 2024 Results

Feb 4, 2025, 7:00 AM EST - 1 year ago

Evolent Health Announces Changes to Board of Directors

Jan 27, 2025, 5:00 PM EST - 1 year ago

Evolent To Release Fourth Quarter 2024 Financial Results on Thursday, February 20, 2025

Dec 18, 2024, 4:10 PM EST - 1 year ago

Evolent announces Dr. Von Nguyen as incoming Chief Medical Officer, effective January 1

Nov 12, 2024, 2:37 AM EST - 1 year ago

Evolent Health: A Shot At Revival After Market Bruising

Nov 9, 2024, 9:12 AM EST - 1 year ago

Evolent Health, Inc. (EVH) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 8:47 AM EST - 1 year ago

Sweetgreen Posts Downbeat Results, Joins Evolent Health, Redfin, Pinterest And Other Big Stocks Moving Lower In Friday's Pre-Market Session

PINS RDFN SG

Nov 7, 2024, 4:10 PM EST - 1 year ago

Evolent Announces Third Quarter 2024 Results

Oct 11, 2024, 8:00 AM EDT - 1 year ago

Evolent To Release Third Quarter 2024 Financial Results on Thursday, November 7, 2024

Oct 2, 2024, 12:08 PM EDT - 1 year ago

Evolent Health Inc (EVH) Stock Price Down 3.2% on Oct 2

Aug 23, 2024, 9:00 AM EDT - 1 year ago

Evolent Health: Let The Bidding Begin

Aug 22, 2024, 1:22 PM EDT - 1 year ago

Exclusive: Evolent Health in sale talks after inbound interest, sources say

Aug 8, 2024, 9:18 PM EDT - 1 year ago

Evolent Health, Inc. (EVH) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:10 PM EDT - 1 year ago

Evolent Announces Second Quarter 2024 Results

Jul 11, 2024, 8:00 AM EDT - 1 year ago

Evolent To Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Jun 4, 2024, 7:00 AM EDT - 1 year ago

Evolent signs agreement to acquire artificial intelligence utilization management products and team from Machinify

May 9, 2024, 4:15 PM EDT - 2 years ago

Evolent and Careology form strategic care navigation partnership to enhance cancer care in the U.S.

May 9, 2024, 4:10 PM EDT - 2 years ago

Evolent Announces First Quarter 2024 Results

Apr 18, 2024, 4:30 PM EDT - 2 years ago

Evolent To Release First Quarter 2024 Financial Results on Thursday, May 9, 2024

Feb 22, 2024, 10:34 PM EST - 2 years ago

Evolent Health, Inc. (EVH) Q4 2023 Earnings Call Transcript

Feb 22, 2024, 4:10 PM EST - 2 years ago

Evolent Announces Fourth Quarter and Full Year 2023 Results

Feb 14, 2024, 4:10 PM EST - 2 years ago

Evolent Adds Russell Glass, Headspace CEO, to Board of Directors

Jan 25, 2024, 7:00 AM EST - 2 years ago

Evolent to Release Fourth Quarter 2023 Financial Results on Thursday, February 22, 2024

Dec 5, 2023, 10:59 PM EST - 2 years ago

Evolent Health, Inc. Announces Pricing of $350.0 Million of Convertible Senior Notes Due 2029 to Pay Down Senior Term Loan

PeakedSeller Mar. 14 at 1:13 PM

0 · Reply

PeakedSeller Mar. 14 at 1:11 PM

0 · Reply

PeakedSeller Mar. 14 at 1:06 PM

0 · Reply

St0ckJunkie13 Mar. 13 at 5:56 PM

$EVH hitting the floor, cant realistically see profit until 2028

1 · Reply

PatBtmn Mar. 13 at 5:42 PM

$EVH ouch

0 · Reply

TOMKiLA Mar. 12 at 1:43 PM

1 · Reply

PeakedSeller Mar. 12 at 12:00 AM

0 · Reply

PeakedSeller Mar. 11 at 11:53 PM

0 · Reply

St0ckJunkie13 Mar. 11 at 4:29 PM

1 · Reply

riedela Mar. 11 at 1:51 PM

$EVH 2.92 buying back my 120k shares all the way to bottom (again) had 230k at one point at 3.64 average. Sad times 😒 if I held 😞

1 · Reply

buyabdhodler Mar. 10 at 3:42 PM

$EVH might as well buy here with a gap down on the weekly chart at least for a trade should easily fill that before going lower

0 · Reply

TOMKiLA Mar. 10 at 1:16 PM

$EVH between the first and second quarters, we need to expect new interesting deals for more than $400M + revenues and 40m new ebitda With good news evolent will double or triple the value, without it the price should be in the 2/4$ range. Next year the revenue should be $3.2/3.4b if u want to see profits with 240/270m ebitda (less than 10% they are looking for but its reasonable numbers) AI investment will drive the cut of some costs like employees and energy costs. Probably if evolent will cut 10/12% of employees costs, the margin will be so much better (like 25/35m $ saved)

0 · Reply

BPler Mar. 9 at 8:45 PM

$EVH I am enjoying these prices to be honest :)

0 · Reply

PHILMYWALLET Mar. 9 at 2:32 PM

$EVH

0 · Reply

PHILMYWALLET Mar. 6 at 7:53 PM

$EVH

0 · Reply

TOMKiLA Mar. 6 at 12:33 PM

$EVH The reality is this: the market is betting on Evolent's failure because its debt had reached $1 billion and because there are always serious losses, plus a loss of revenue and EBITDA! In 2026, however, there is already positive news about Evolent's future; both growth this year and next year. EBITDA could double in 2027 thanks to the fact that margins and AI investments are already proving successful. Evolent is a company that, as soon as it sees concrete results from AI, it will easily reduce fixed and variable costs by 10-15%, and we will also see net profits! Time for changes! This is why I bought 8k shares in the last 14 months, the price should be 10/15$ with 200m ebitda easily

0 · Reply

PatBtmn Mar. 5 at 8:23 PM

$EVH manipulation by the most utterly corrupt useless cumscum in the universe

0 · Reply

PHILMYWALLET Mar. 5 at 6:02 PM

$EVH how many of you have sold on this board?

2 · Reply

PHILMYWALLET Mar. 5 at 4:30 PM

$EVH this is brutal

0 · Reply

TOMKiLA Mar. 4 at 5:14 PM

$EVH probably we need to expect other good info in the coming 2 quarters to see a strong increase of price

0 · Reply

RKwine Mar. 3 at 4:27 PM

$EVH Jumped in this morning based only on EVH symbol, Van Halen🤘

2 · Reply

TOMKiLA Mar. 3 at 3:43 PM

$EVH imagine if evolent should close green :)

1 · Reply

Market Cap	333.80M
Revenue (ttm)	1.88B
Net Income (ttm)	-534.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-28.49%
Debt to Equity Ratio	2.34

Volume	2,716,200
Avg Vol	3,227,236
Day's Range	N/A - N/A
Shares Out	111.64M
Stochastic %K	11%
Beta	0.24
Analysts	Strong Sell
Price Target	$5.61